| Name | GX-585 |
| Description | GX-585 is a sulfonamide analog that is a Nav 1.7 channel inhibitor with analgesic activity for the study of neuropathic pain and inflammation. |
| In vitro | GX-585 is a potent inhibitor of NaV1.7 and highly selective for NaV1.5, but has different selectivity among neuronal NaV channels, with weaker inhibition of tetrodotoxin-resistant sodium currents in mouse DRG neurons, indicating weaker affinity for NaV1.8, with GX-585 blocking IC50 of 11.7 μM.[1] |
| In vivo | METHODS: In an animal model of acute injury, the effects of once daily (q.d.) oral administration of 3 mg/kg and 10 mg/kg GX-585 were evaluated 2 hours after the first, fifth, or twelfth daily dose.
RESULTS: A single 10 mg/kg dose of GX-585 produced analgesic effects similar to repeated 3 mg/kg doses 2 hours after administration, but the activity was completely reversed after 24 hours. Thus, the long-term effects of repeated dosing are inconsistent with slow losses of the compound from plasma. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | SodiumChannel | Sodium Channel | Olfr895-Agonist-10 | Olfr895Agonist10 | Olfr895 Agonist-10 | Olfr895 Agonist 10 | Nav1.7 channel | MDK-3673 | MDK 3673 | GX-585 |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Dibucaine |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Sodium Channel Targeted Library | Neuroprotective Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Ion Channel Targeted Library |
United States
